Comparative Pharmacology
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus DRIXORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXCHLORPHENIRAMINE MALEATE versus DRIXORAL.
DEXCHLORPHENIRAMINE MALEATE vs DRIXORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexchlorpheniramine maleate is a histamine H1 receptor antagonist that competitively blocks the effects of histamine at peripheral H1 receptors, reducing symptoms of allergic reactions such as vasodilation, increased vascular permeability, and smooth muscle contraction. It also has anticholinergic and sedative properties.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
2 mg orally every 4-6 hours; maximum 12 mg/day
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
None Documented
None Documented
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateTerminal elimination half-life is 20-24 hours in healthy adults, allowing once or twice daily dosing. Prolonged in hepatic impairment or elderly.
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Primarily renal (approximately 70-80% as unchanged drug and metabolites, mainly glucuronide conjugates); minor biliary/fecal elimination (20-30%).
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Category C
Category C
Antihistamine
Antihistamine/Decongestant
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."